Final results of the real-life observational VICTOR-6 study on metronomic chemotherapy in elderly metastatic breast cancer (MBC) patients

被引：3

作者：

Trevisan, B. ^{[1
]}

Pepe, F. F. ^{[1
]}

Vallini, I. ^{[2
]}

Montagna, E. ^{[3
]}

Amoroso, D. ^{[4
]}

Berardi, R. ^{[5
]}

Butera, A. ^{[6
]}

Cagossi, K. ^{[7
]}

Cavanna, L. ^{[8
]}

Ciccarese, M. ^{[9
]}

Cinieri, S. ^{[10
]}

Cretella, E. ^{[11
]}

De Conciliis, E. ^{[12
]}

Febbraro, A. ^{[13
]}

Ferrau, F. ^{[14
]}

Ferzi, A. ^{[15
]}

Baldelli, A. ^{[16
]}

Fontana, A. ^{[17
]}

Gambaro, A. R. ^{[18
]}

Garrone, O. ^{[19
]}

Gebbia, V. ^{[20
]}

Generali, D. ^{[21
]}

Gianni, L. ^{[22
]}

Giovanardi, F. ^{[23
]}

Grassadonia, A. ^{[24
]}

Leonardi, V. ^{[25
]}

Sarti, S. ^{[26
]}

Musolino, A. ^{[27
]}

Nicolini, M. ^{[22
]}

Putzu, C. ^{[28
]}

Riccardi, F. ^{[29
]}

Santini, D. ^{[30
]}

Sarobba, M. G. ^{[31
]}

Schintu, M. G. ^{[32
]}

Scognamiglio, G. ^{[33
]}

Spadaro, P. ^{[34
]}

Taverniti, C. ^{[35
]}

Toniolo, D. ^{[36
]}

Tralongo, P. ^{[37
]}

Turletti, A. ^{[38
]}

Valenza, R. ^{[39
]}

Valerio, M. R. ^{[40
]}

Vici, P. ^{[41
]}

Clivio, L. ^{[42
]}

Torri, V. ^{[42
]}

Cazzaniga, M. E. ^{[1
]}

机构：

[1] Azienda Osped San Gerardo, Monza, Italy

[2] Osped Circolo & Fdn Macchi, Varese, Italy

[3] European Inst Oncol, Milan, Italy

[4] Osped Versilia, Camaiore, Italy

[5] Azienda Osped Univ Osped Riuniti, Torrette, Italy

[6] Nuovo Osped San Giovanni Dio, Florence, Italy

[7] Osped Ramazzini, Carpi, Italy

[8] Azienda Osped Piacenza, Piacenza, Italy

[9] Osped Vito Fazzi, Lecce, Italy

[10] Osped A Perrino, Brindisi, Italy

[11] Osped Bolzano, Bolzano, Italy

[12] ASL Asti, Asti, Italy

[13] Osped S Cuore Gesu Fatebenefratelli, Benevento, Italy

[14] Osped San Vincenzo, Taormina, Italy

[15] Azienda Osped Osped Civile Legnano, Magenta, Italy

[16] Osped San Salvatore, Coppito, Italy

[17] Azienda Osped Univ Pisana, Pisa, Italy

[18] ASST Fatebenefratelli Sacco, Milan, Italy

[19] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy

[20] Osped La Maddalena, Palermo, Italy

[21] Ist Ospitalieri Cremona, Cremona, Italy

[22] Osped Infermi, Rimini, Italy

[23] AUSL Romagna, Emilia Romagna, Italy

[24] Osped SS Annunziata, Taranto, Italy

[25] Osped Civ, Palermo, Italy

[26] IRCCS Ist Sci Romagnolo Studio Cura Tumori, Meldola, Italy

[27] Osped Parma, Parma, Italy

[28] Azienda Osped Univ, Sassari, Italy

[29] Osped Antonio Cardarelli, Naples, Italy

[30] Univ Campus Biomed, Rome, Italy

[31] Osped San Francesco, Nuoro, Italy

[32] Osped Giovanni Paolo II, Lecce, Italy

[33] Osped Valduce, Como, Italy

[34] Casa Cura Villa Salus Messina, Messina, Italy

[35] Osped Molinette, Turin, Italy

[36] Osped Circolo, Rho, Italy

[37] Osped Umberto I, Rome, Italy

[38] Osped Martini, Turin, Italy

[39] PO Vittorio Emanuele, Gela, Italy

[40] AOU Policlin Paolo Giaccone, Palermo, Italy

[41] INT Regina Elena, Rome, Italy

[42] IRCCS Mario Negri Inst Pharmacol Res, Milan, Italy

来源：

SCIENTIFIC REPORTS | 2023年 / 13卷 / 01期

关键词：

PHASE-II TRIAL; 1ST-LINE TREATMENT; INTERNATIONAL SOCIETY; ORAL VINORELBINE; CAPECITABINE; MANAGEMENT; RECOMMENDATIONS; ANGIOGENESIS; PACLITAXEL; WOMEN;

D O I：

10.1038/s41598-023-39386-x

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Nowadays, treatment of metastatic breast cancer (MBC) has been enriched with novel therapeutical strategies. Metronomic chemotherapy (mCHT) is a continuous and frequent administration of chemotherapy at a lower dose and so whit less toxicity. Thus, this strategy could be attractive for elderly MBC patients. Aim of this analysis is to provide insights into mCHT's activity in a real-life setting of elderly MBC patients. Data of patients & GE; 75 years old included in VICTOR-6 study were analyzed. VICTOR-6 is a multicentre, Italian, retrospective study, which collected data on mCHT in MBC patients treated between 2011 and 2016. A total of 112 patients were included. At the beginning of mCHT, median age was 81 years (75-98) and in 33% of the patients mCHT was the first line choice. Overall Response Rate (ORR) and Disease Control Rate (DCR) were 27.9% and 79.3%, respectively. Median PFS ranged between 7.6 and 9.1 months, OS between 14.1 and 18.5 months. The most relevant toxicity was the hematological one (24.1%); severe toxicity (grade 3-4) ranged from 0.9% for skin toxicity up to 8% for hematologic one. This is a large study about mCHT in elderly MBC patients, providing insights to be further investigated in this subgroup of frail patients.

引用

页数：9

共 50 条

[41] Bevacizumab plus chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results
Aparicio, T.
Bouche, O.
Taieb, J.
Maillard, E.
Kirscher, S.
Etienne, P. -L.
Faroux, R.
Akouz, F. Khemissa
El Hajbi, F.
Locher, C.
Rinaldi, Y.
Lecomte, T.
Lavau-Denes, S.
Baconnier, M.
Oden-Gangloff, A.
Genet, D.
Paillaud, E.
Retornaz, F.
Francois, E.
Bedenne, L.
ANNALS OF ONCOLOGY, 2018, 29 (01) : 133 - 138
[42] Real-World Experience among Elderly Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitor-Based Therapy
O'Connor, Thomas N.
Schultz, Emily
Wang, Jianxin
O'Connor, Tracey
Levine, Ellis
Knudsen, Erik S.
Witkiewicz, Agnieszka K.
CANCERS, 2024, 16 (09)
[43] Real-World Data on Apatinib Efficacy-Results of a Retrospective Study in Metastatic Breast Cancer Patients Pretreated With Multiline Treatment
Liu, Zhaoyun
Shan, Jing
Yu, Qian
Wang, Xinzhao
Song, Xiang
Wang, Fukai
Li, Chao
Yu, Zhiyong
Yu, Jinming
FRONTIERS IN ONCOLOGY, 2021, 11
[44] Quality of life of 1276 elderly patients with prostate cancer, starting treatment with a gonadotropin-releasing hormone agonist: results of a French observational study
Lebret, Thierry
Culine, Stephane
Davin, Jean-Louis
Hennequin, Christophe
Mignard, Jean-Pierre
Moreau, Jean-Luc
Rossi, Dominique
Zerbib, Marc
Mahmoudi, Abdel
Latorzeff, Igor
AGING MALE, 2014, 17 (02) : 87 - 93
[45] Bevacizumabplus chemotherapy as first-line treatment for patients with metastatic colorectal cancer: Results from a large German community-based observational cohort study
Stein, Alexander
Petersen, Volker
Schulze, Mathias
Seraphin, Joerg
Hoeffkes, Heinz-Gert
Valdix, Anette R.
Schroeder, Jan
Herrenberger, Julia
Boxberger, Frank
Leutgeb, Barbara
Hinke, Axel
Kutscheidt, Andreas
Arnold, Dirk
ACTA ONCOLOGICA, 2015, 54 (02) : 171 - 178
[46] Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
J. Salvador
L. Manso
J. de la Haba
A. Jaen
E. Ciruelos
M. C. de Villena
M. Gil
A. Murias
A. Galan
C. Jara
J. Bayo
J. M. Baena
J. Casal
J. R. Mel
I. Blancas
P. Sanchez Rvira
Clinical and Translational Oncology, 2015, 17 : 160 - 166
[47] Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
Salvador, J.
Manso, L.
de la Haba, J.
Jaen, A.
Ciruelos, E.
de Villena, M. C.
Gil, M.
Murias, A.
Galan, A.
Jara, C.
Bayo, J.
Baena, J. M.
Casal, J.
Mel, J. R.
Blancas, I.
Sanchez Rvira, P.
CLINICAL & TRANSLATIONAL ONCOLOGY, 2015, 17 (02) : 160 - 166
[48] Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02)
Park, Yeon Hee
Jung, Kyung Hae
Im, Seock-Ah
Sohn, Joo Hyuk
Ro, Jungsil
Ahn, Jin-Hee
Kim, Sung-Bae
Nam, Byung-Ho
Oh, Do Youn
Han, Sae-Won
Lee, Soohyeon
Park, In Hae
Lee, Keun Seok
Kim, Jee Hyun
Kang, Seok Yun
Lee, Moon Hee
Park, Hee Sook
Woo, Sook Young
Jung, Sin-Ho
Ahn, Jin Seok
Im, Young-Hyuck
BREAST CANCER RESEARCH AND TREATMENT, 2015, 152 (01) : 77 - 85
[49] Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study
Blackwell, Kimberly L.
Burstein, Harold J.
Storniolo, Anna Maria
Rugo, Hope S.
Sledge, George
Aktan, Gursel
Ellis, Catherine
Florance, Allison
Vukelja, Svetislava
Bischoff, Joachim
Baselga, Jose
O'Shaughnessy, Joyce
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (21) : 2585 - 2592
[50] Improving Chemotherapy-Induced Peripheral Neuropathy in Patients with Breast or Colon Cancer after End of (Neo)adjuvant Therapy: Results from the Observational Study STEFANO
Zaiss, Matthias
Uhlig, Jens
Zahn, Mark-Oliver
Decker, Thomas
Lehmann, Helmar C.
Harde, Johanna
Hogrefe, Cathrin
Vannier, Corinne
Marschner, Norbert
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (11) : 613 - 621

← 1 2 3 4 5 →